Alembic Pharmaceuticals gets USFDA nod for generic antidepressant tablets

Alembic Pharmaceuticals has received final approval from the USFDA for its generic version of Brexpiprazole tablets, used in treating major depressive disorder and schizophrenia. The approval covers strengths from 0.25 mg to 4 mg, and the market size for these tablets is estimated at USD 2 billion for the year ending September 2024.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0xuA6hD
via IFTTT